The Global Nonalcoholic
Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor,
Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail
Pharmacy, and Online Pharmacy), and by Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,119.8
million in 2017 (based on existing approved therapies including anti-diabetics,
vitamins, dietary supplements, and others) and is projected to exhibit a CAGR
of 42.7% over the forecast period (2018 - 2026).
Nonalcoholic fatty liver disease
(NAFLD) is a condition which occur due to the presence of fat in more than 5%
of liver cells. NAFLD affects people who consume little or no alcohol. According
to the Harvard Medical School, January 2018 report, NAFLD is the most common
liver disease and affects nearly 25% of American adults, 60% of whom were men.
It increases the risk of heart disease and if left untreated, it can lead to
nonalcoholic steatohepatitis (NASH), a condition causing inflamed liver. More
than 40% of people with NAFLD develop NASH which can lead to scarring of the
liver. Severe liver scarring, known as cirrhosis, increases the risk of liver
cancer.
The most widely used treatment for
NASH is to eliminate potential causes and risk factors such as weight loss and
treatment for hyperglycemia or dyslipidemia. A study published by the National
Center for Biotechnology Information in 2015, suggests that thiazolidinediones
and vitamin E can help correct biochemical and histologic abnormalities in
NASH.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2279
Moreover, no medicines have been
approved to treat NASH so far. However, researchers are developing medicines to
improve the conditions. According to the National Institute of Diabetes and Digestive
and Kidney Diseases, some studies suggest that pioglitazone (Actos), a medicine
for type 2 diabetes, can improve NASH in people non-diabetic patients.
Companies in the market are
focusing on extensive research to develop medicine for NASH treatment. For
instance, in 2017, Gilead Sciences, Inc. announced results from a Phase 2,
randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral,
investigational inhibitor of Acetyl-CoA carboxylase, in patients with
nonalcoholic steatohepatitis.
Browse 26 Market Data Tables and
28 Figures spread through 187 Pages and in-depth TOC on "Nonalcoholic
Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva,
and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy,
and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa) - Global Forecast to 2026"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/nonalcoholic-steatohepatitis-treatment-market-2279
Key Takeaways of the Nonalcoholic
Steatohepatitis Treatment Market:
The global nonalcoholic
steatohepatitis treatment market is expected to expand at a CAGR of 42.7%
during the forecast period (2018–2026), owing to increasing incidences of
nonalcoholic fatty liver disease. According to the State of Obesity data, in
2016, approximately 100 million individuals in the U.S were suffering from have
nonalcoholic fatty liver disease.
Among region, Asia Pacific is
expected to grow at highest rate owing to increasing population with diabetes
owing to the rising prevalence of diabetes driven by a combination of factors
including sedentary lifestyles, rapid urbanization, and unhealthy diets.
According to the WHO, diabetes is a growing challenge in India with estimated
8.7% diabetic population in the age group of 20 and 70 years.
Major players operating in the
global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc.,
Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals
Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk,
Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2279
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging market
trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment